FDA-approved Esketamine, marketed as “Spravato”, offers hope to adults battling treatment-resistant depression (TRD) and Major Depressive Disorder (MDD). Derived from Ketamine, it's a self-administered nasal spray used in combination with prescription antidepressants and delivered under the supervision of professionals who have both medical and psychiatric training.
Esketamine works by blocking NMDA receptors and boosting glutamate levels in the brain while prompting brain cells to forge new communication pathways to quickly alleviate depressive symptoms. Patients undergoing Esketamine are monitored before, during, and after dosing and may experience symptoms such as dissociation, feeling “loopy”, transient increase in blood pressure, nausea, or drowsiness; all which generally resolves within 2 hours. In clinical trials between active and “placebo” Esketamine, the treatment response in the active group experienced great symptom improvement.
Furthermore, published reports showed that the individuals in the active group were able to sustain the positive effects of treatment over time. This treatment may be covered by your insurance and the dedicated team at Butler Hospital will assist in the administrative steps to seek coverage on your behalf.
Butler Hospital
345 Blackstone Boulevard
Providence, RI 02906
P: (401) 455-6632
Determining Eligibility:
To learn more about Esketamine treatment at Butler Hospital, call: (401) 455-6632 or submit your information to BRAIN@CareNE.org for a team member to contact you within 48 hours.
For Referring Providers:
For clinicians, if you would like to refer your patient for consideration of Esketamine, please download and complete this form and fax to (401) 455-6686.
Esketamine, marketed under the brand name Spravato, is the first FDA-approved treatment version of a drug commonly known as “Ketamine” for treatment-resistant depression. It is taken as a nasal spray that is self-administered in our clinic.
Patients may experience a range of side effects, including feelings of dissociation, nausea, drowsiness, temporary increase in blood pressure, or feeling “loopy.” However, these side effects tend to peak at 40 minutes and wear off by the end of the dosing visit.
You will be scheduled for a consultation with one of our providers; during which we will review your medical history, clinical history, and current symptoms. We will ask you to complete an EKG and lab work (both can be done at Butler Hospital) and submit any necessary paperwork on your behalf to the insurance company for prior authorization. Upon approval, a member of our team will schedule the first visit with you.
The standard treatment consists of three phases:
The visit typically lasts about two hours to monitor for any adverse reactions.
While effective, Esketamine requires close supervision due to potential side effects including,
Other, rare side effects include respiratory arrest or risk of abuse and dependence.
Avoid eating for two hours and refrain from liquids 30 minutes before your appointment.
Esketamine (Spravato) is a more potent form of Ketamine, administered intranasally, and has shown efficacy in targeting depressive symptoms and reducing suicidal thoughts.
Yes, Esketamine treatment can be used in conjunction with your on-going medication regimen. Some drugs may interact with Esketamine so our providers may advise to hold a certain medication prior to your dosing visit. Any decisions regarding your medication with be communicated with your outpatient prescriber for coordination of care.
Esketamine may be covered by your insurance, but coverage can vary depending on your specific plan. Our team will assist in determining possible co-payments for treatments and seek out insurance pre-authorization on your behalf if Esketamine is covered and appropriate for you.
Copyright © 2023 Care New England Health System